



State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: May 14, 2024

TO: All Louisiana Medicaid Prescribing Providers and Pharmacists

FROM: Kimberly Sullivan, Medicaid Executive Director *KLS*

SUBJECT: Louisiana Medicaid Pharmacy Point of Sale Edits for Vonoprazan (Voquezna®), Sitagliptin (Zituvio™), and Budesonide (Eohilia™) – July 2024

Effective July 1, 2024, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement new Point of Sale (POS) edits for select medications. The edits apply to pharmacy claims submitted to Gainwell for FFS and to Magellan for MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, and UnitedHealthcare).

Point of Sale Therapeutic Duplication of Vonoprazan (Voquezna®) with Proton Pump Inhibitors (PPIs)

An incoming pharmacy claim for vonoprazan (Voquezna®) will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for a proton pump inhibitor and vice versa with the following:

Denial from Gainwell (FFS Only): **NCPDP rejection code 88** (DUR Reject Error) mapped to **EOB code 482** (Therapeutic Duplication).

Denial from Magellan (MCO Only): **NCPDP rejection code 88** (DUR Reject Error) mapped to internal code 31141 with message "TD-Therapeutic Duplication/Overlap."

MCO and FFS: After consultation with the prescriber, the pharmacist may override the denial by submitting the following override codes at POS:

439-E4 Field (Reason for Service Code) **TD** (Therapeutic Duplication)
440-E5 Field (Professional Service Code) **MØ** (Prescriber Consulted)
441-E6 Field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Point of Sale Therapeutic Duplication of Sitagliptin (Zituvio™) with GLP-1

Agonists

An incoming pharmacy claim for sitagliptin (Zituvio™) will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for a GLP-1 receptor agonist and vice versa with the following:

Denial from Gainwell (FFS Only): **NCPDP rejection code 88** (DUR Reject Error) mapped to **EOB code 482** (Therapeutic Duplication).

Denial from Magellan (MCO Only): **NCPDP rejection code 88** (DUR Reject Error) to internal code 31141 with message "TD-Therapeutic Duplication/Overlap."

MCO and FFS: After consultation with the prescriber, the pharmacist may override the denial by submitting the following override codes at POS:

439-E4 Field (Reason for Service Code) **TD** (Therapeutic Duplication)

440-E5 Field (Professional Service Code) **MØ** (Prescriber Consulted)

441-E6 Field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Point of Sale Maximum Dose Edit for Sitagliptin (Zituvio™)

An incoming pharmacy claim for sitagliptin (Zituvio™) which exceeds the maximum daily dose (100mg/day) will deny with the following:

Denial from Gainwell (FFS Only): **NCPDP rejection code 88** (DUR Reject Error) mapped to **EOB code 529** (Exceeds Maximum Daily Dose).

Denial from Magellan (MCO Only): **NCPDP rejection code 88** (DUR Reject Error) to internal code 280 with message "HD-High Dose Alert."

MCO and FFS: After consultation with the prescriber, the pharmacist may override the denial by submitting the following override codes at POS:

NCPDP 439-E4 field (Reason for Service Code) – **HD** (High Dose)

NCPDP 440-E5 field (Professional Service Code) – **MØ** (Prescriber Consulted)

NCPDP 441-E6 field (Result of Service Code) – **1G** (Filled with Prescriber Approval)

Point of Sale Age Limit for Budesonide (Eohilia™)

Incoming pharmacy claims for budesonide (Eohilia™) will deny when the recipient is less than 11 years of age on the date of service with:

Denial from Gainwell (FFS Only): **NCPDP rejection code 60** (Product/Service Not Covered for Patient Age) mapped to **EOB code 234** (P/F Age Restriction).

Denial from Magellan (MCO Only): NCPDP rejection code 60 (Product/Service Not Covered for Patient Age) mapped to internal error code 2193.

Point of Sale Duration of Therapy for Budesonide (Eohilia™)

Pharmacy claims for budesonide (Eohilia™) in which the duration of therapy exceeds 12 weeks will deny with:

Denial from Gainwell (FFS Only): NCPDP rejection code 88 (DUR reject error) mapped to **EOB code 656** (Exceeds Maximum Duration of Therapy).

Denial from Magellan (MCO Only): NCPDP rejection code 76 mapped to internal code 7003 with message “Max 12 weeks of therapy.”

MCO and FFS: After consultation with the prescribing provider, the pharmacist may override the maximum duration of therapy by submitting:

NCPDP 439-E4 field (Reason for Service Code) - **MX** (Excessive Duration)

NCPDP 440-E5 field (Professional Service Code) **MØ** (Prescriber Consulted)

NCPDP 441-E6 field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Additional Information:

Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which is inclusive of the *Louisiana Uniform Prescription Drug Prior Authorization Form*, medication list, criteria, and diagnosis code list.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

FFS pharmacy claims should be submitted to Gainwell Technologies. MCO pharmacy claims should be submitted to Magellan.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

Healthcare Provider	Pharmacy Help Desk	Pharmacy Help Desk Phone Number
Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, UnitedHealthcare	Magellan	(800) 424-1664
Fee for Service	Gainwell Technologies	(800) 648-0790

LA Medicaid Pharmacy POS Edits- July 2024

May 14, 2024

Page 4

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

KS/MBW/GJS

c: Healthy Louisiana Plans
 Melwyn B. Wendt
 Gainwell Technologies
 Magellan